Want to see KR:228760 full AI Analyst Report?
Top Page
Genomictree, Inc.
(228760)
Select Model
Select Model
Rating:44Neutral
Price Target:
₩9,438.00
Action:N/A
Date:10/28/26
The score is held down primarily by weak operating fundamentals (persistent losses, volatile revenue, and ongoing cash burn) and a bearish technical trend (price below key moving averages with negative MACD). A solid, low-leverage balance sheet provides some downside support, but valuation remains challenged given negative earnings and no dividend data.
Positive Factors
Low Leverage
The very low debt burden limits refinancing pressure and preserves financial flexibility while Genomictree continues investing in research and development. A sizable equity base provides a meaningful cushion against operating volatility and gives management more capacity to fund initiatives without relying heavily on external borrowing.
Negative Factors
Persistent Operating Losses
Deeply negative operating and net margins indicate that current revenue levels do not cover the company’s cost base. Unless margin improvement becomes substantial and sustained, continued losses can consume equity, restrict reinvestment capacity, and delay the point at which the diagnostics platform can fund itself.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
The very low debt burden limits refinancing pressure and preserves financial flexibility while Genomictree continues investing in research and development. A sizable equity base provides a meaningful cushion against operating volatility and gives management more capacity to fund initiatives without relying heavily on external borrowing.
Read all positive factors
Genomictree, Inc. (228760) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩242.55B
Dividend YieldN/A
Average Volume (3M)105.86K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue Growth-17.13%
EPS Growth1.63%
CountryKR
EmployeesN/A
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-334.06
Shares Outstanding24,859,201
10 Day Avg. Volume85,716
30 Day Avg. Volume105,855
Financial Highlights & Ratios
PEG Ratio3.41
Price to Book (P/B)3.59
Price to Sales (P/S)109.82
P/FCF Ratio-41.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-145
Revenue Forecast (FY)₩7.80B
Genomictree, Inc. Business Overview & Revenue Model
Company Description
Genomictree Inc is a molecular diagnostics firm focused on innovating technologies that address critical, unmet demands within the healthcare industry....
Genomictree, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
76
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.83B | 3.76B | 2.36B | 3.42B | 29.87B | 5.14B |
| Gross Profit | 366.31M | 73.36M | -726.56M | -270.02M | 24.99B | 2.52B |
| EBITDA | -7.20B | -10.28B | -8.90B | -6.27B | 3.02B | -5.80B |
| Net Income | -8.02B | -8.99B | -10.24B | -8.76B | -6.24B | -11.42B |
Balance Sheet | ||||||
| Total Assets | 125.97B | 120.76B | 130.68B | 132.84B | 162.91B | 177.15B |
| Cash, Cash Equivalents and Short-Term Investments | 75.39B | 77.37B | 96.08B | 93.15B | 114.61B | 130.53B |
| Total Debt | 55.19M | 2.37B | 2.08B | 1.83B | 29.18B | 38.44B |
| Total Liabilities | 2.50B | 5.45B | 6.36B | 7.81B | 55.35B | 62.05B |
| Stockholders Equity | 123.17B | 115.07B | 123.88B | 124.74B | 107.05B | 115.10B |
Cash Flow | ||||||
| Free Cash Flow | -11.60B | -9.97B | -16.19B | -11.17B | 2.46B | -19.46B |
| Operating Cash Flow | -8.80B | -7.24B | -13.63B | -10.88B | 4.29B | -7.63B |
| Investing Cash Flow | -15.15B | -2.93B | -11.49B | 8.12B | 14.07B | -49.07B |
| Financing Cash Flow | 5.68B | 182.05M | 6.02B | -20.50B | -19.52B | 62.87B |
Genomictree, Inc. Technical Analysis
Negative
―
Price Trends
10888.60
Negative
11404.20
Negative
15451.80
Negative
Market Momentum
-382.61
Negative
45.43
Neutral
77.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:228760, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 10444.00, equal to the 50-day MA of 10888.60, and equal to the 200-day MA of 15451.80, indicating a bearish trend. The MACD of -382.61 indicates Negative momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 77.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:228760.
Genomictree, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | ₩36.42B | 15.76 | ― | ― | -3.47% | 98.69% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | ₩249.70B | -2.64 | ― | ― | 84.72% | -480.97% | |
44 Neutral | ₩242.55B | -63.16 | ― | ― | -17.13% | 1.63% | |
43 Neutral | ₩302.45B | -16.97 | ― | ― | 116.74% | -482.50% | |
41 Neutral | ₩48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
KR:228760
Genomictree, Inc.
9,900.00
-9,770.00
-49.67%
KR:002630
ORIENTBIO, Inc.
1,229.00
-987.00
-44.54%
KR:011000
GeneOne Life Science, Inc.
2,670.00
-7,680.00
-74.20%
KR:064550
Bioneer Corporation
6,980.00
-7,500.00
-51.80%
KR:199800
ToolGen Incorporated
30,950.00
-25,409.59
-45.08%
KR:950210
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
4,155.00
-8,525.00
-67.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.